CD209 signaling pathway as a biomarker for cisplatin chemotherapy response in small cell lung cancer

作     者：Anqi Lin Hong Yang Jian Zhang Peng Luo Anqi Lin;Hong Yang;Jian Zhang;Peng Luo

作者机构：Department of OncologyZhujiang HospitalSouthern Medical UniversityGuangzhouGuangdong 510282China The First Clinical Medical SchoolSouthern Medical UniversityGuangzhouGuangdong 510515China 

出 版 物：《Genes & Diseases》 (基因与疾病（英文）)

年 卷 期：2024年第11卷第3期

页      面：11-14页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：cisplatin chemotherapy lung 

摘      要：One of the bottlenecks in the clinical treatment of small cell lung cancer(SCLC)is its susceptibility to multidrug *** SCLC is sensitive to platinum-based chemotherapy at the initial stage of treatment,it can rapidly become drug-resistant,allowing tumor growth to accelerate.A significant decrease in drug sensitivity after recurrence and multidrug resistance can seriously interfere with the effectiveness of treatment,making sensitivity maintenance one of the urgent challenges to be ***,discovering prognostic markers for cisplatin chemotherapy and understanding the mechanisms of cisplatin resistance have great practical significance for improving the outcomes of sCLC patients.